Study S002113

Investigation on Safety, Tolerability and Bioavailability of Oral NN9924 in Healthy Male Subjects

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01037582
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 155
Start: 2009-12-17
Primary completion: 2010-05-07
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Diabetes Mellitus, Type 2; Healthy
Interventions: DRUG:NN9924 (oral); DRUG:placebo; DRUG:NN9924 (s.c.); DRUG:NN9924 (i.v.)
Results posted: FALSE
Secondary identifiers: EUDRACT_NUMBER:2009-012366-31; OTHER:U1111-1112-7564; NIH:2009

Registered primary outcomes

Number and severity of adverse events (AEs) recorded [from dosing to Day 22]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0016569	Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes. Granhall C, Clinical pharmacokinetics	2019	Randomized trial	PMID 30565096 DOI	cites ClinicalTrials.gov:NCT01037582; registry reference DERIVED:30565096